Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.
2.

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL.

N Engl J Med. 1996 Nov 28;335(22):1621-9.

3.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ.

N Engl J Med. 1999 Aug 5;341(6):385-93.

4.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.

N Engl J Med. 1994 Nov 3;331(18):1173-80.

5.

Update on vertical HIV transmission.

Groginsky E, Bowdler N, Yankowitz J.

J Reprod Med. 1998 Aug;43(8):637-46. Review.

PMID:
9749412
6.

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Moye J Jr, Glenn Fowler M, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA 3rd, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H.

J Infect Dis. 1999 Mar;179(3):567-75.

PMID:
9952362
7.

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival.

Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, Huang S, Sperling RS, Cunningham B, Gandia J, Maupin R, Zorrilla CD, Jones T, O'Sullivan MJ; Pediatrics AIDS Clinical Trials Group 288 Protocol Team.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):170-81.

PMID:
12571527
8.

Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand.

Jourdain G, Mary JY, Coeur SL, Ngo-Giang-Huong N, Yuthavisuthi P, Limtrakul A, Traisathit P, McIntosh K, Lallemant M; Perinatal HIV Prevention Trial Group, Thailand.

J Infect Dis. 2007 Dec 1;196(11):1629-36. Epub 2007 Oct 25.

PMID:
18008246
9.

Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Bhadrakom C, Simonds RJ, Mei JV, Asavapiriyanont S, Sangtaweesin V, Vanprapar N, Moore KH, Young NL, Hannon WH, Mastro TD, Shaffer N.

AIDS. 2000 Mar 31;14(5):509-16.

PMID:
10780713
10.

Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus.

Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, Baum JB, Tesoriero JM, Savicki R.

N Engl J Med. 1998 Nov 12;339(20):1409-14.

12.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Suksomboon N, Poolsup N, Ket-Aim S.

J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review.

PMID:
17489882
13.

A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.

Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, Boyle E, Chitsike I, Chipato T, Gottesman M, Silverman M.

Clin Infect Dis. 2007 Jan 1;44(1):111-9. Epub 2006 Nov 22.

PMID:
17143826
14.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF.

N Engl J Med. 1999 Aug 5;341(6):394-402.

15.

Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?

Bollen LJ, Whitehead SJ, Mock PA, Leelawiwat W, Asavapiriyanont S, Chalermchockchareonkit A, Vanprapar N, Chotpitayasunondh T, McNicholl JM, Tappero JW, Shaffer N, Chuachoowong R.

AIDS. 2008 Jun 19;22(10):1169-76. doi: 10.1097/QAD.0b013e3282fec42a.

PMID:
18525263
16.

Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group.

Matheson PB, Abrams EJ, Thomas PA, HernĂ¡n MA, Thea DM, Lambert G, Krasinski K, Bamji M, Rogers MF, Heagarty M.

J Infect Dis. 1995 Aug;172(2):353-8.

PMID:
7622877
17.

Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV.

Traisathit P, Mary JY, Le Coeur S, Thantanarat S, Jungpichanvanich S, Pornkitprasarn W, Gomutbutra V, Matanasarawut W, Wannapira W, Lallemant M.

J Obstet Gynaecol Res. 2009 Apr;35(2):225-33.

PMID:
19708170
18.

Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone.

Simpson BJ, Shapiro ED, Andiman WA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):145-52.

PMID:
9052723
19.
20.

HIV infection and zidovudine use in childbearing women.

Sia J, Paul S, Martin RM, Cross H.

Pediatrics. 2004 Dec;114(6):e707-12. Epub 2004 Nov 15.

PMID:
15545619

Supplemental Content

Support Center